Phase II, Open Label, Randomized Comparative Trial of Ondansetron Alone versus the Combination of Ondansetron and Aprepitant for the Prevention of Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Regimens Containing High-Dose Cytarabine

Table 5

Adverse events.

Adverse events	(%) with any grade			(%) with grades 1-2		(%) with grades 3-4
	Overall	OND	OND + APR	OND	OND + APR	Overall	OND	OND + APR
Diarrhea	23 (26)	11 (26)	12 (27)	10 (23)	11 (25)	3 (3)	1 (2)	2 (5)
Headache	22 (25)	11 (26)	11 (25)	11 (26)	9 (20)	2 (2)	0 (0)	2 (5)
Fatigue	18 (21)	9 (21)	9 (20)	9 (21)	9 (20)	0 (0)	0 (0)	0 (0)
Constipation	17 (19)	7 (16)	10 (23)	7 (16)	10 (23)	0 (0)	0 (0)	0 (0)
Indigestion	9 (10)	3 (7)	6 (14)	3 (7)	6 (14)	0 (0)	0 (0)	0 (0)
Edema	8 (9)	3 (7)	5 (11)	3 (7)	5 (11)	0 (0)	0 (0)	0 (0)
Abdominal pain	5 (6)	2 (5)	3 (7)	2 (5)	3 (7)	0 (0)	0 (0)	0 (0)
Dizziness	3 (3)	1 (2)	2 (5)	1 (2)	2 (5)	0 (0)	0 (0)	0 (0)
Syncope	1 (1)	1 (2)	0 (0)	0 (0)	0 (0)	1 (1)	1 (2)	0 (0)
Hypotension	1 (1)	0 (0)	1 (2)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)